An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.